Lepu Pharmaceutical's Compound Antihypertensive Drug Valsartan Amlodipine Tablets (Ⅰ) has entered the administrative approval stage

Recently, Lepu Pharmaceuticals entered the administrative examination and approval stage for the production of valsartan and amlodipine tablets (I), which is a generic version of Category 4, and is expected to be approved for marketing in the near future
.
Valsartan Amlodipine Tablets (I) is a compound antihypertensive drug.

Valsartan and Amlodipine Tablets (I), the original research company of Novartis, is a single-tablet compound preparation composed of angiotensin receptor antagonist valsartan and calcium channel antagonist amlodipine, suitable for valsartan single drug treatment or amlodipine monotherapy in patients with inadequate blood pressure control
.

According to the data of Minet.
com, in 2020, the total sales of valsartan and amlodipine tablets (I) in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and China's urban physical pharmacy terminals more than 2.
5 billion yuan
.

No matter in medical institutions or physical pharmacies, the market size of valsartan and amlodipine tablets (I) shows an upward trend year by year
.
It is worth mentioning that in recent years, the terminal sales growth rate of Valsartan Amlodipine Tablets (I) in Chinese urban physical pharmacies has exceeded 20%.

Sales of Valsartan and Amlodipine Tablets (I) in Chinese urban physical pharmacies (unit: ten thousand yuan)

Source: Minet.

Although the valsartan and amlodipine tablets (I) of 9 domestic companies have been approved for batch production and are deemed to have been reviewed, there are still more than 10 pharmaceutical companies' applications for this product under review, and Lepu Pharmaceuticals has registered this product.

Data source: Minet database, NMPA